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CONCURRENT CHEMORADIOTHERAPY IN THE TREATMENT OF LOCALLY 
ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK 
Dr Aoakhum Kichu*, Prof Dr S. Shanmugakumar, Prof Dr N. V. Kalaiyarasi, Dr Baskar, Dr 
Madhumati, Dr Sundaraesan, Dr Prabagaran, Dr Sanjal, Dr Vijay Karthick 
AIMS AND OBJECTIVES: 
 To assess the immediate Loco regional response rates and to assess the toxicity 
profile of locally advanced squamous cell carcinoma of the head and neck treated with weekly 
Cisplatin and Daily Gefitinib 
MATERIALS AND METHODOLOGY: 
This was a Phase II single arm study where 30 consecutive eligible patients were 
included in the study. All patients received a total of 66 Gy of Radiation in 2 Gy per fraction 
along with weekly Cisplatin 30mg/m2 and daily tablet Gefitinib 250mg throughout the course of 
radiation. The immediate locoregional response was assessed after 6 weeks by clinical 
examination and radiological imaging. The toxicity profile of the treatment was assessed with 
RTOG acute morbidity scoring criteria. 
RESULTS 
Out of the 30 patients recruited for the study 25 were males and oropharynx and 
hypopaharynx were the most common subsites. All patients were able to complete the full course 
of RT and chemotherapy. Overall 76.6% patients had complete response and 23.3% partial 
response during assessment after 6 weeks of completion of treatment. Oropharyngeal, 
hypopharyngeal and laryngeal cancers had good response to the treatment. All patients 
developed some form of mucositis during the treatment but the rates of grade 3 and 4 mucositis 
were low. Only 1 patient developed the classical skin toxicity associated with the use of 
gefitinib. 
CONCLUSIONS: 
Concurrent chemoradiotherapy with cisplatin and Tablet gefitinib in locally advanced  head and 
neck cancer is a feasible treatment alternative with manageable toxicity, good patient compliance 
and good response to treatment. Large scale study is needed to show a significant benefit of the 
addition of gefitinib to the standard treatment protocol.   
 
Keywords: concurrent chemoradiation, cisplatin, Gefitinib, anti-EGFR therapy, single arm 
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INTRODUCTION 
Cancer of any site is a dreaded diagnosis for a patient and it 
has a profound impact, not only on the patients’ own physical, 
emotional well being, but it also affects the lives of those around 
them.  The burden of head and neck cancer in the world is large and 
significant, being the 6
th
 most common type of cancer overall. In 
India the incidence is even higher and is one of the most common 
type of cancer. The incidence also varies according to the 
geographic distribution and the local habits. Its incidence highly 
correlates with the abuse of tobacco in its various forms and the 
synergistic effect of its combination with its partner in crime, 
alcohol.  
There is a general increasing trend in the incidence of cancer 
worldwide.  Developing countries like ours contribute the major 
portion of the new cancer cases worldwide. High incidence of oral 
cavity cancer is reported from Australia, India, South Africa and 
Western Europe
1
. Cancer incidence is highest in India amongst the 
SAARC countries
2
. 
Majority of the patients present in the locally advanced stage 
where they are treated with a combination of all the three major 
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modalities of oncology- surgery, chemotherapy and radiotherapy. 
However even with the best of therapy the overall 5 year survival 
amongst this group hovers around the 50% mark, and it is even less 
in a developing country like ours. And even with all the recent 
advances in therapeutics in all the three fields there has been no 
significant change in the survival. 
In India, cancer of the head and neck ranks amongst the 
second most common in males and the fourth most common in 
females. Head and neck cancer is the fourth most common cause of 
death in the 25-69 years age group following cardiovascular 
disease, respiratory disease and tuberculosis
2
. Hence it is no 
coincidence that head and neck cancers create a major burden on 
the country as it effects a population group which forms the major 
productive part, whether it be economically or socially.  
According to a WHO report, at any point there are 2.5 million 
cancer patients in India of which a third is formed by the head and 
neck cancer group. This incidence also varies according to the 
geographic location and the habits of the local people which expose 
them to the causative agents of cancer, mainly tobacco which can 
be in various forms like Paan, Gutkha, smoking, etc.   
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Along with cancer, other non communicable diseases like 
cardiovascular disease, diabetes, hypertension have emerged as the 
main cause of morbidity and mortality as compared to the non 
infectious diseases. Cancer and these other non communicable 
diseases have become a big public health problem and concern. 
Hence we are closely catching up with the western population in 
terms of pattern of disease prevalence. 
 But our health care system is still lacking behind with many 
regions not equipped enough to provide the standard treatment that 
is being followed in the western countries, especially when it comes 
to cancer. The government has initiated a number of ways to bring 
about the causes of cancer and means to take preventive measures, 
especially against the use of tobacco. Advertisements promoting 
tobacco and its products have been taken off air and warning labels 
mentioning that use of tobacco causes cancer is displayed on every 
product containing tobacco. Also the media is being used to create 
awareness on how use of tobacco leads to cancer. 
Inspite of all the aggressive campaign waged against tobacco, 
the rates of tobacco addiction, especially amongst the younger 
generation is increasing and as a result the incidence of tobacco 
related cancer in general and head and neck cancer in particular 
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continues to show an increase. There is also an increasing number 
of cancers in the younger adults reflecting the widespread of 
tobacco products amongst this group.    
AETIOLOGY AND RISK FACTORS: 
Man is his own worst enemy and he tries again and again in 
several ways to bring about destruction upon himself. The most 
common cause of cancer worldwide is the use of tobacco in its 
various forms. The risk associated with the use of tobacco and 
cancer is proven beyond doubt. And it is like common knowledge 
where even the least educated is aware that it can cause cancer and 
a number of other debilitating diseases. Inspite of this the use of 
tobacco is rampant and the cancer continues to increase. Here we 
talk about the various risk factors for head and neck cancer 
TOBACCO 
The use of tobacco has been documented as early as 1400-
1000BC where native American people smoked the plant during 
special/sacred occasions or seal bargains. They believed it to be a 
gift from their creator and the exhaled smoke carried the persons’ 
thoughts or prayers to the creator. The use of tobacco was further 
popularized with the arrival of the Europeans and it was used as a 
popular trade item. From there it spread throughout the world 
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where it was smoked mostly for leisure. Now the tobacco industry 
has become a multibillion dollar industry worldwide.  
It is estimated that 43% of cancer deaths are due to tobacco, 
inactive lifestyles, unhealthy diets, and alcohol consumption
3
.Of 
these, tobacco use is the world’s most avoidable cause of cancer. 
There are 1.2 billion smokers and hundreds of millions of 
smokeless tobacco users in the world
4,5
. When it comes specifically 
to head and neck cancer the national cancer institute reported that 
85% of the patients had history of tobacco use. The use of tobacco 
strongly correlates with the development of head and neck 
squamous cell carcinoma. 
SMOKING 
 Smoking is the most popular form of using tobacco and is 
prevalent across cultures. Whatever the form or the nomenclature, it 
basically involves the inhalation of the smoke cause by burning 
tobacco. The major carcinogens present in tobacco smoke are PAH 
(polycyclic aromatic hydrocarbons), NNK [4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanol] andNNN(N1-nitroso nor nicotine). 
Nicotine, the most commonly known ingredient of tobacco by itself 
is not carcinogenic but it is a psychostimulant and is responsible to 
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the addictiveness to tobacco, hence leading to repeated exposures to 
the carcinogenic substances. 
Worldwide filtered cigarettes are most commonly used 
whereas in India the use of Beedis is very common. As compared 
with cigarettes the carcinogenic load is higher for Beedis as it has a 
higher puff rate. 
SMOKELESS TOBACCO 
The use of smokeless tobacco in the form of gutkha, khaini, 
paan and their combined use  with other irritants like arecanuts, 
slake lime etc contributes a significant amount to the formation of 
oral cancers.  
ALCOHOL 
The partner in crime alcoholism is a habit that goes hand in 
hand with the use of tobacco. More of a lifestyle choice where a 
person taking either one is more likely to take the other. Its like the 
addiction to one leads to the addiction to the other, hence it 
resembles a synergistic relationship. In this context the use of 
alcohol has a synergistic effect with tobacco enhancing the cancer 
causing effect. 
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A meta-analysis from 26 studies of oral and pharyngeal 
cancers found that consumption of  25, 50, or 100 g pure 
alcohol/day1 was associated with a pooled relative risk (RR) of 
1.75, 2.85, and 6.01, respectively, of oral and pharyngeal cancer. 
Also the use of alcohol leads to a variety of other health problems 
which in turn affects the cancer outcome and survival. 
ROLE OF HUMAN PAPILLOMA VIRUS 
The role of HPV infection and cancer is well proven in 
cervical cancer. And now its role is being extensively studied in 
head and neck cancer also. In several studies the presence of the 
HPV virus in aquamous cell carcinoma of the head and neck is well 
documented with a range of around 30-35%. The rate is even higher 
in oropharyngeal cancers.HPV infection is proved to be one of the 
causative factor in SCCHN.  
As in cervical cancer, the viral genes are incorporated into the 
host genome leading to the production of the oncoproteins E6 and 
E7 which inactivates the P53 and initiates carcinogenesis. Overall 
such patients have a better response to chemotherapy and radiation 
and has a better prognosis as compared to HPV negative tumours.  
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OTHER RISK FACTORS 
A variety of other risk factors like sharp tooth, iron 
deficiency anemia (Plummer vinson syndrome), vitamin A 
deficiency, spicy foods etc are implicated in the development of 
cancer. Rarely head and neck cancer may develop in the presence 
of genetic abnormalities like Fanconi Anemia (FA), Ataxia 
Telangiectasia, Blooms Syndrome, & Li-Fraumeni Syndrome etc. 
CLINICAL FEATURES AND PRESENTATION 
The symptoms depend on the site of the primary and the 
nodal involvement. Tumors of the oral cavity usually present  as an 
ulcer or growth. Non healing ulcers are also a common 
presentation. Tumours in the pharynx can lead to dysphagia or 
odynophagia. Laryngeal cancers presents with hoarseness or change 
in voice, difficulty in breathing. Many a times, patient came with a 
complaint of a swelling in the neck due to metastasis to lymph 
nodes. 
HISTOLOGICAL CLASSIFICATION 
By far the most common histology is squamous cell 
carcinoma and its variants. Squamous cell carcinoma is classically 
divided into three. Well differentiated, moderately differentiated 
and poorly differentiated. Tis classification is based on the degree 
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of keratinisation of the cells. And it is well known that as the tumor 
becomes less differentiated, the prognosis also worsens.  The rest 
are adenocarcinomas salivary gland tumours, melanomas, 
lymphomas, sarcomas etc.  
SYMPTOMS: 
Most common presenting symptom is ulcer(or 
ulceroprolifertive lesion) followed by  pain, difficulty in 
swallowing (dysphagia), pain during swallowing (odynophagia), 
difficulty in breathing (dyspnea), change in voice, and neck 
swelling because of lymph nodal involvement. Other generalized 
symptoms are cough, weight loss, loss of appetite may cause further 
detoriation with treatment like concurrent chemoradiation. 
Nutritional status of the patient plays a major role in treatment 
outcome.  
In advanced stages, patients present with large painful masses 
and symptoms due to spread to adjacent structures. Many patients 
also have a poor nutritional status and general at the time of 
presentation which can have a big part to play in deciding the 
treatment policy. It is also important to assess the patients mental, 
social and emotional 
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WORK UP OF THE PATIENT 
The work up of the patient before the deciding the treatment 
policy is very important. A proper history and clinical examination 
is a must. Assessment of the general condition of the patient should 
involve the measurement of the height and weight, the presence of 
anemia and other comorbities. Frequently, due to the common use 
of tobacco and alcohol in such patients, many of them have other 
comorbid conditions.  
Routine blood investigations are a must to check for anemia 
and assess the patients’ bone marrow reserve. To assess the liver 
and the renal functions. It is also important to do the viral markers 
like HIV, Hepatitis B, C etc. ENT examinations in the form of 
Indirect and direct laryngoscopy, video laryngoscopy, diagnostic 
nasal endoscopy etc are all important investigations. This helps in 
assessing the primary lesion and also helps to look for  other 
malignancies as the entire aerodigestive tract is exposed to the 
carcinogens, causing field cancerisation. In the same way, a upper 
GI Endoscopy also will provide additional information.  
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A CT and/or MRI of the head and neck is a must to see the 
extent of the primary disease and the nodal burden which is 
important for staging as well as planning of Radiotherapy as well as 
planning for the surgery. An imaging of the chest either in the form 
of a plain X-ray or CT or MRI can be if clinically indicated to rule 
out metastasis to the lung and also to see for and co-morbid lung 
condition. A PET scan may be considered for stage III-IV diseases 
and in those with large nodal disease in the lower neck.     
OVERVIEW OF TREATMENT FOR HEAD AND NECK 
CANCER 
The treatment of cancer has evolved and is still evolving. All 
the three major fields in cancer treatment have undergone major 
changes throughout the ages. However the management of head and 
neck cancer is complex. It requires a multi-disciplinary approach 
where inputs from all the specialities are required to design a 
optimum treatment for the patient. Also it should be an 
individualized treatment taking into consideration not only the 
stage of the disease but also the performance status and co-
morbidities. The patient should be looked at as a whole.  
While it is important not to compromise on the oncological 
principles, the cosmetic and functional outcome should also not be 
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ignored. Specially considering that the face is the representation of 
a person, even slight alterations can cause a lot of psychological 
trauma. Also we are dealing with an area which required for a lot of 
functions like speaking, respiration, eating, emotional expressions, 
etc are all related with the face. So it is imperative that the 
treatment should allow the person to live as normal a live as 
possible without compromising on the disease control and survival.  
Hence it is a fine balance that has to be achieved. Even 
though the management of head and neck cancer has come a long 
way, the optimum is yet to be achieved. Finally the patients’ wishes 
have to be taken into consideration after proper explanations about 
the pros and cons of each modality of treatment.     
SURGERY 
It is the oldest modality in the treatment of cancer. Emerging 
from the history of cancer treatment surgery plays a major role. For 
ages, surgery has been the primary and only modality. From cutting 
out whatever growth is seen to now where a adequate margins are 
given along with reconstruction wherever possible ensuring the best  
cosmetic and functional outcome, surgery has come a long way. 
And with the development of robotic surgery, it will only lead to 
better outcomes.  
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It is important that all cases should be evaluated by a surgical 
oncologist before treatment. And a coordinated effort with the 
medical and radiation oncologist and other specialist like plastic 
and ENT surgeons is needed.   
Surgery is the modality of choice in early stage cancers 
especially of the oral cavity. However in sites like the 
hypopharynx, larynx, where the resection of the tumor is difficult 
or may result in significant loss of function, other approaches like 
RT can be considered.   
A decision has to be made as to whether the tumor is 
resectable or not. Resectable basically means to be able to remove 
the whole tumor along with adequate margins. Adequate margins 
means a margin of 1.5-2cm. If the margin of is less than 0.5cm it is 
termed as a close margin. Positive margin means the presence of 
tumor or carcinoma in situ component at the resected margin.  
However the term resectability and unresectability are 
relative terms, depending on the surgeons capabilities and 
experience. A tumor that may appear to be unresectable to one may 
be resecatable to the other.  
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A patients’ cancer may be termed unresectable if  a surgeon 
and/or his team feels the cannot remove all gross tumor on 
anatomic grounds or if they are certain local control will not be 
achieved after surgery (even with the addition of RT to the 
treatment approach). These tumors usually involve the cervical 
vertebrae, brachial plexus, deep muscles of the neck or the carotid 
artery. Also tumor involvement of certain sites associated with a 
poor prognosis like direct extension of disease to involve the 
external skin, direct extension to the mediastinal structures or 
prevertebral fascia makes them unresectable.  
Finally it is important to distinguish unresectable tumours 
from inoperable tumors, where even though the primary tumor is 
resectable the general condition of the patient does not allow for a 
operative procedure. Additionally a subgroup of patients will refuse 
surgical intervention, but these should not be termed as 
unresectable.  
In patients with distant metastasis, even though the 
locoregional disease may be surgically treatable, such patient are 
usually treated as though the primary tumour is unresectable.  
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There is also a subgroup of patients who can be adequately 
treated without surgery. They form an important group. RT alone or 
in combination with chemotherapy may offer a more attractive 
approach to these cancers without the morbidities of surgery.  
Addressing the nodal disease is also very important as they 
are frequent sites for disease failure. Historically neck dissection 
have been classified as radical or modified.   
Radical neck dissection involves removal of the superficial 
and deep cervical fascia with its enclosed lymph nodes (levels I to 
V). Along with that the sternocleidomastoid muscle, the omohyoid 
muscle, the internal and external jugular veins, cranial nerve XI, 
and the submandibular gland are also removed.  
Modified procedures involved the preservation of structures 
like the sternocleidomastoid muscle, Jugular vein and spinal 
accessory nerve.  
Type I—cranial nerve XI is spared;  
Type II—cranial nerve XI and the internal jugular vein are 
spared;  
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Type III (functional)—cranial nerve XI, the internal jugular 
vein, and the sternocleidomastoid muscle are spared.  
Another term is selective neck dissection where the lymph 
node levels at greatest risk are removed selectively.  
A new nomenclature has been defined where neck dissections 
are classified into either comprehensive or selective. In 
comprehensive neck dissection, all lymph node levels that would be 
removed in a classical radical neck dissection are removed i.e. level 
I-V. And it doesn’t matter whether the other three structures, the 
sternocleidomastoid, the jugular vein or the cranial nerve XI are 
removed or not.  
In selective neck dissection, only those with a high risk for 
involvement from that particular primary are dissected. It is mostly 
recommended for N0 disease. For example, for a oral cavity lesion 
with a N0 disease, a selective neck dissection would include 
removal of nodes found above the omohyoid, commonly level I -III 
and sometimes the superior part of level V. For a laryngeal or 
pharyngeal primary, the recommendation is removal of level II -IV 
and and level VI when appropriate. For infraglottic cancers an 
elective dissection of the level VI nodes is considered.  
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In general <10% of head and neck cancer patients who do not 
have any clinically positive nodes will have nodal metastasis 
beyond the confines of a appropriate selective neck dissection. 
Hence in most patients a selective neck dissection is more than 
appropriate to achieve a good disease control. 
In general a comprehensive nodal dissection is recommended 
for those with large nodal burden, like N3 disease. Selective neck 
dissection is recommended for clinically N0 disease. In certain 
patients with N1 or N2 disease selective neck dissection may be 
appropriate and can reduce the morbidity in these patients. 
Another important aspect is to whether to proceed with a 
ipsilateral neck dissection or a bilateral one. Bilateral dissection is 
recommended for tumors at or near the midline and for those with 
bilateral drainage.  
 Another important role of surgery is in the form of a salvage 
treatment. In patients who have been treated with non surgical 
methods like chemo radiation, if there is a failure to control the 
disease, then surgical excision of the residual or recurrent lesion 
can be done. Such patients have to be kept under careful follow-up 
so that the disease can be caught early and managed appropriately.  
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RADIOTHERAPY 
The field of radiation oncology has come a long way since the 
discovery of X-rays by William Roentgen in 1895. Then the 
realization that these X-rays can be used for killing tumor cells and 
also the discovery of radium by Marie Curie were the initial stages 
from where Radiotherapy has grown into one of the major arms for 
the treatment of cancer.  
Radiation can be used as the primary modality or as an 
adjunct to surgery. The main advantage of radiation is that it allows 
for the organ to be preserved resulting in less morbidity as 
compared to surgery. Radiation can be administered alone or in 
combination with chemotherapy and both have a synergistic effect. 
It can be given as a pre-operative treatment to allow for downsizing 
of the tumor resulting in better resectability and decreasing volume 
of tissue that needs to be resected.  
It can be administered after surgery to produce a better 
locoregional control especially in those with locally advanced 
disease, with positive margins or extra-capsular extension, in those 
with lymphovascular invasion, deep infiltration of tumor all of 
which have a higher chance of recurrence.  
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Radiation can be the only form of treatment in early stage 
small volume lesions where it achieves local control comparable 
with that of surgery. And in those with locally advanced cancers 
where surgery is not possible or where a organ and functional 
preservation is desired, radiation along with the combination of 
chemotherapy can be used.  
Radiation can be delivered in the form of external beam 
radiation (EBRT) or brachytherapy. The aim of radiation therapy 
has been to deliver the maximum possible dose to the tumor and the 
minimum to the normal tissues. With the developments in the 
radiation delivery systems we are now able to more closely adhere 
to this philosophy. From 2D RT to 3D conformal RT to Intensity 
modulated RT, we are able to better spare the normal tissues from 
the deleterious effects of RT while at the same time delivering a 
substantial dose to the tumor. 
There are now different methods of delivering RT which has 
been modified from the conventional fractionation. Conventional 
fractionation is 2 Gy per day for 5 days a week. The available data 
suggests that at least 1000cGy has to be delivered in fractionated 
schedules per week tom achieve a good tumor control. The altered 
fractionations are hyperfractionation and accelerated fraction.  
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In Hyperfractionated RT there is an increase in the number of 
fractionations, a significant increase in the dose, a significant 
reduction in the dose per fraction and no significant change in the 
overall treatment time. It exploits the different sensitivities of the 
tumor cells and normal cells to RT and the ability of the two cell 
types to repair the damage caused by radiation.  
In accelerated Fractionation the overall treatment time is 
decreased so as to negate the accelerated repopulation that takes 
place in tumour cells aftyer the initial exposure to RT. It can be 
pure, where conventional dose fractionation is used. It can be 
hybrid, where the dose fractionation is altered.  
In a major study conducted by the  RTOG conventional 
fracxtionation was compared with hyperfractionated RT, split 
course accelerated  RT and concomitant boost regimen. In this 
study the found that Concomitant boost and hyperfractionation  
group yielded a significantly better control as compared to the 
standard conventional fractionation. Split course RT did not 
provide any significant advantage.  A important point to be noted 
was that the altered regimens had significantly higher acute toxicity 
rates. However the late complication rates were similar in all the 
groups. 
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Brachytherapy is another way of therapy where the radiation 
source is kept in close proximity to the tumour. It canbe used as a 
form of boost to the tumour after initial EBRT or it can be used 
alone in small early stage disease. Its advantage is that the dose 
delivered is highly conformal and there is minimal damage to the 
adjacent normal tissue. 
Another area where radiation plays a major role is in the 
palliative setting. A significant proportion of patients, especially in 
our country where many patients present in the very advanced stage 
where surgical resection is not possible and we cant expect to 
achieve a cure with our chemoradiation. Also many of these 
patients present with a poor general condition where the patient 
will not be able to tolerate all the radical procedures. In such 
patients palliative radiation can be given to relieve symptoms like 
pain, bleeding, etc.  
CHEMOTHERAPY  
Chemotherapy too plays a very important role in the 
management of head and neck cancer. In the curative setting it acts 
as a radiosensitiser, enhancing the effects of radiation leading to 
more cell kill. Also it too has its own cytotoxic effect leading to an 
increased response when given together with radiation. It also takes 
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care of any microscopic, undetected metastasis at a distant site 
which might not be detected at the initial presentation.  
There is a recent increasing trend in the use of neo-adjuvant 
chemotherapy before starting the primary treatment. This helps to 
decrease the burden of the disease leading to better resectability or 
better response to radiation. However multiple large scale trials 
have not shown any consistent benefit with the use of induction 
chemotherapy on the overall outcome. However with the 
development o newer drugs and newer combination of 
chemotherapy, induction chemotherapy remains an attractive 
option.  
Chemotherapy is also indicated in combination with 
radiotherapy in those with a positive margins or extracapsular 
extension in the post operative histopatholgy. In patients with 
recurrent or metastatic disease not amenable for a curative attempt 
by surgery or radiation, chemotherapy plays a major role. 
Numerous trials have shown survival benefit with the use of 
chemotherapy in such patients. But it is important to balance 
between the expected benefit and the associated toxicity of 
chemotherapy.  
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EFGR AND TARGETED THERAPY 
  The Epidermal Growth factor receptor (EGFR) is 
a cell membrane receptor that belongs to the ErbB family of 
receptors. The ErbB family consist of four closely related receptor 
tyrosine kinases  
 EGFR (ErbB-1) 
 HER2 (ErbB-2) 
 Her3 (ErbB-3) 
 Her4 (ErbB4) 
 
Figure 1. The EFGR pathway 
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   EGFR is normally present in cells and helps to 
perform a number of functions. It was first discovered by Stanley 
Cohen of Vanderbilt University. It is activated by a number of 
ligands including the epidermal growth factor and transforming 
growth factor – alpha. After the binding of the ligand it forms a 
homodimer which leads to activation and autophosphorylation of 
the tyrosine kinase residues in the intracellular domain of the 
receptor. It can also form heterodimers with other members of the 
ErbB family leading to activation of the tyrosine kinases. EGFR are 
can also be activated in the absence of ligands like in the setting of 
mutations or stressful conditions like under radiation. 
Once the tyrosine kinases are activated it initiates a number 
of downstream pathways like  the MAPK, Akt and JNK pathways 
which eventually lead to DNA synthesis and cell proliferation. In 
tumor cells it can lead to cell proliferation, tumor invasion, 
metastases, increased cell survival and anti apoptotic signals.  
It is well known that EGFR over expression is seen in over 
90% of head and neck cancers. And high levels of EGFR are 
associated with decreased survival, resistance to radiotherapy, 
locoregional failure and increased rate of distant metastases.  
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EGFR was proposed as a pathway for targeted therapy based 
on intial researches that EGFR was frequently over expressed in 
epithelial tumors. With improved understanding of the oncogenic 
role of EGFR,its mechanism of action, the discovery of somatic 
mutations and other mutations in the components of the singling 
pathway, the prospect of targeting this receptor has become even 
more attractive.    
Basically there are two groups of drugs against EGFR, they 
are the monoclonal antibodies MABs and the Tyrosine Kinase 
Inhibitors TKIs. The first of the monoclonal antibodies was 
cetuximab and other subsequent drugs include panitumumab, 
nimotuzomab. They target the extracellular receptor ligand binding 
site preventing the activation of thee receptor and its activation. 
The TKIs are smaller molecules that target the intracellular tyrosine 
kinases that are activated through the extracellular binding of the 
ligand to the receptor. The activation of the tyrosine kinases 
initiates a series of pathways that eventually lead to the action of 
EGFR.  
These targeted therapies have proven its role in lung cancer 
where the TKIs like Gefitinib and Erlotinib and more recently 
Afatinib has shown to improve the progression free survival and 
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also the overall survival in patients having mutations in the EGFR 
gene. Several trials have proven effect of anti-EGFR therapy. 
The anti EGFR drugs have also been tried in a number of 
other sites showing a varied results. It has been use in cancers of 
the colorectum, pancreas, CNS, etc.    In head and cancer 
cetuximab was the first drug that was shown to have improved 
benefit in the setting of locally advanced head and neck cancer 
when it was added to Radiation. It has also improved the overall 
survival in the recurrent and metastatic head and neck cancer when 
used in combination of chemotherapy. Other anti EGFR drugs are 
being investigated in various trials across the world. 
DESCRIPTION OF THE DRUGS 
The drugs that are used in this trial are Cisplatin and 
Gefitinib.  
CISPLATIN 
Cis-diaaminedichloroplatinum is a platinum analogue that 
covalently binds to DNA analogue with preferential binding to the 
N-7 position of guanine and adenosine and causus the production of 
crosslinks that eventually lead to inhibition in DNA synthesis. It 
can also bind to nuclear cytoplasmic proteins resulting in cytotoxic 
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effects. Apart from its cytotoxic effect it also acts as a 
radiosensitizer for radiation.      
It is given parenterally and is widely distributed in plasma 
with less than 10% remaining in the plasma after I hour of infusion. 
Inside the cells it undergoes a aquation reaction where a chlrode 
molecule is replaced by a water molecule leading to the production 
of a highly reactive species which causes the cell damage. It  is 
excreted mainly through the kidney.  
The main toxicities of cisplatin include 
 Nephrotoxicity: due to its activity on the renal 
microtubules, it cacuses renal damage. Dose limiting in 
upto 35-40% of patients. It is generally reversible 
however the effect is dose related and can lead to acute 
as well as chronic renal failure. 
 Myelosuppresion: it is seen in 25-30% of patients with 
all the three cel lineages equally effected. As the dose is 
increased, leucopenia and thrombocytopenia are more 
pronounced. 
 Ototoxicity: is also dose related resulting in high 
frequency hearing loss and tinnitus 
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 Neurotoxicity: this is dose related most commonly 
resulting in in peripheral sensory neuropathy. Stocking 
and glove pattern of paresthesias and numbness are 
classically seen. Motor function defect, enceplhalopathy 
and seizures can also occur 
 Nausea and vomiting: it is also a common problem 
with the use of cisplatin. It can occur immediately- 
acute form ot after 24 hours of infusion- delayed form.  
 Other toxicities like alopecia, ocular toxicity 
hypersensitivity, azoospermia, sterility etc can also be 
seen 
Cisplatin forms the first line of chemotherapy in a number of 
cancers including head and neck cancer, lung cancer, blader cancer, 
ovarian and testicular cancer, esophageal cancers, etc. the dose 
usually ranges from 75-100 mg/m
2
 in a three weekly regimen to 30-
40mg/m
2 
 with a weekly regimen. 
 GEFITINIB 
Gefitinib is a small molecule tyrosine kinase inhibitor that 
has specific activity against the EGFR Tyrosine kinase. It causes 
inhibition of EGFR autophosphorylation and inhibition of the 
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EGFR tyrosine kinase that leads to inhibition of critical mitogenic 
and anti-apoptotic signals involve in cell proliferation, metastasis, 
angiogenesis and response to chemoradiation. 
The oral absorption of gefitinib is slow and reaches a peak 
plasma concentration by 3-7 hours of intake. The oral 
bioavailability is approximately 60%. It is extensively bound to 
plasma proteins an extenxively distributed throughout the tissue. A 
steady state drug concentration is reached in 7-10 days. 
It is metabolized in the liver largely by the CYP3A4 
microsomal enzyme. The main metabolite is O-desmethyl 
piperazine derivative which is significantly less potent than the 
parent drug. Most of the drug I excreted in the faeces. Only about 
4% are excrete through renal secretion. The terminal half life of the 
parent drug is 48 hours. 
Gefitinib is mostly used in lung cancers having the EGFR 
mutation. Its role in other epithelial malignancies are still under 
trial. The commonly used dose of gefitinib is 250 mg per oral daily.  
Gefitinib is a relatively safe drug having ,minimal see effects. 
It mostly results in pruritus, dry skin, with a mainly pustular 
acneiform skin rash. The rash is most commonly seen in the face, 
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neck and other sun expose areas of the skin. The skin rash is 
usually less as compared with that seen with the monoclonal 
antibodies. The skin rash is mostly self-limiting and usually 
resolves without without scarring, it can negatively impact the 
treatment compliance and the quality of life. It exposes the skin to 
infections and can also cause treatment discontinuation or dos 
modification, hence it can affect the outcome. 
The EGF Receptor is normally expressed in the epidermis, 
sebaceous glands and hair follicular epithelium where it plays a 
number of important roles for maintaining the health of the skin. 
The exact mechanism of how skin rash is produce is not fully 
known but a possible mechanism is described. With the inhibition 
of the EGFR it causes follicular occlusion and rupture because of 
premature epithelial differentiation an it also causes an increase in 
the genes that initiate inflammation, apoptosis and cell attachment. 
With this defect it also allows for bacterial infection and growth to 
occur which worsens the situation.   
The development of the rash usually follows a well 
regularized timeline 
1) First week- sensory disturbance with erythema and edema 
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2) Weeks 1-3: papulopustular eroptions manifest 
3) Week 4- crusting of the lesions 
4) Week4-6: even with successful treatment, the erythema and 
dry skin may continue to persist General measures for the 
prevention and management of rash include: 
 To take appropriate sun protection. Exposure to sun increases 
the severity of the rash 
 avoid activities and skin care products that causes of skin like 
taking long hot showers, alcohol based or perfumed products, 
and other acne medications. Greasy ointments are to be 
avoided. Moisturizers and alcohol free emollient creams can 
be used 
 topical clindamycin 2% is recommended for mild to moderate 
grade skin rash. 
 Medium potency steroids like 1% hydrocortisone can be used 
for mild to severe skin rash as it inhibits the inflammation 
 In moderate to severe skin rash, oral antibiotics like 
minocycline or doxycycline are recommended in addit ion to 
the topical antibiotics 
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 Deferring of the anti-EGFR if the symptoms do not improve 
within 1-2 weeks 
 If the rash is severely symptomatic with necrosis, blistering 
petechial and purpuric lesions, a expert opinion from the 
dermatologist should be obtained.  
Other toxicities of gefitinib include elevations in blood 
pressure, especially in those with hypertension, increase in the liver 
enzymes, anorexia, mild nausea or vomiting, and rarely hemoptysis 
and GI hemorrhage.  
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REVIEW OF LITERATURE 
In patients with locally advanced head and neck cancer not 
amenalble ti surgery radiation along with chemotherapy has 
emerged as the treatment modality of choice. The most commonly 
used method of delivering radiation is the conventional 
fractionation\ method where 200cGY is delivered 5 times per week. 
This method was first widely used by Fletcher et al. This method 
was thought to provide the best compromise between the tumour 
cell kill and normal tissue sparing allowing sufficient time for the 
recovery of the normal cells from the effects of radiation. But now 
with better understanding of the radiobiology of the tumor as well 
the normal cells new forms of treatment have been devised that 
allows for better therapeutic ratio to be attained i.e. increased 
tumour control probability and decreased normal tissue toxicity. 
These are the modified fractionation schedules. 
The EORTC in their landmark trial 2279 compared 
conventional fractionation with hyperfractionated RT. Here patients 
were divided into two groups with one arm receiving the 
conventional fractionation of 70 Gy in 2Gy per fraction five 
fractions per week while the other arm received hyperfractionated  
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RT of 80.5 Gy delivered in 70 fractions, 1.15 Gy per fraction 
delivered as twice daily schedules with a interval of 4-6 hours 
between the fractions. At the end of the trial there was a 219% 
significant increase in the locoregional control and a non 
statistically significant improvement in the overall survival.  The 
acute toxicity was enhanced in the hyperfractionated arm but the late 
toxicity between the two arms was similar .
6 
In another trial (Danish DAHANCA 8 trial) accelerated 
radiotherapy was compared with conventional RT. In this trial there 
was a 15% improvement in the locoregional control and as with the 
hyperfractionated RT trial, there was an increase in the acute 
toxicities but the late toxicities were similar.
7 
Till now the combination of chemotherapy with radiation has 
provided the best results in terms of tumour control and overall 
survival. There are several trials that have investigated the use of 
chemotherapy along with radiation using a variety of different 
chemo drugs and RT schedules and altering the timing of when the 
patient is exposed to the chemotherapy. An important meta-analysis 
of these trials is the MACH-NC Trial which proved that the 
concurrent use of chemotherapy along with radiation has the best 
results.  
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MACH- NC 
The initial publication of the MACH – NC (meta- analysis 
of chemotherapy in headand neck) study analysed data from 
RCTs from 1965 to 1993 and published the findings. Since then an 
update including 24 new trials have been published. Data of abuout 
10,000 patients from 63 trials were analysed. In the control arm the 
overall survival was 32 % at 5 years. It was found that the use of 
chemotherapy at any time of treatment resulted in an absolute 
benefit of 4% which meant that it increased the 5 year survival 
from 32% to 36%
8
. 
The analysis also found that the timing of chemotherapy had 
a significant impact on the overall outcome. The greatest benefit 
was seen with the use of chemotherapy concurrently with an 
absolute benefit of 8% improvement in the overall survival at the 
end of 5 years.  The use of adjuvant chemotherapy resulted in a 
absolute benefit of 1%  while the use of induction chemotherapy 
resulted in a benefit of 2%. 
In the updated MACH-NC which included trials performed 
from 1993-2000 and included 24 new trials the absolute benefit that 
was seen with the use of chemotherapy did not change i.e. 4%. And 
as in the previous publication the benefit od neoadjuvant and 
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adjuvant chemotherapy is not clear.  And irrespective of the type of 
fractionation use the benefit seen with the use of concurrent 
chemoradiation is seen. Another important finding is that cisplatin 
based chemotherapy had the most benefit and there was no 
significant difference in those receiving single agent cisplatin or 
combined chemotherapy. Also the effect of chemotherapy is less 
pronounced in older individuals, specially in those older than 70 
years. 
Although three weekly cisplatin is the standard form of 
delivering cisplatin, several trials have emerged that has compared 
three weekly cisplatin with weekly cisplatin and found that there 
was no significant difference between the two in terms of treatment 
outcome. Also high dose cisplatin is associated with a significantly 
higher toxicity and patients compliance is low, hence weekly 
cisplatin which is more better tolerated may become the treatment 
of choice. 
WEEKLY CISPLATIN TRIALS 
In a study by Akihiro Homo et al, where patients with 
locally advanced head and neck cancer were treated with 
conventional RT and weekly cisplatin of 40mg/m2 the overall 
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survival rate and disease free survival were 93.7% and 88% 
respectively. The toxicities were well manageable.
9 
In a single institution experience presented by the Basket 
University in ASCO 2011, they found that there was no significant 
difference in the median overall survival, the locoregional failure 
rate and the distant relapse rates in patients treanted with weekly 
cisplatin as compared with those treated with the three weekly 
regimen. They conclude that theweekly regimen of cisplatin is as 
effective as the three weekly regimen.
10 
In an Indian study conducted at the Tata Memorial Hospital 
where 264 patients of locally advanced headn and neck squamous 
cell carcinoma were treated with conventional RT and weekly 
cisplatin dose of 30mg/m
2
.  They conclude that weekly cisplatin has 
moderate efficacy with acceptable toxicity and has the potential to 
become an optimal therapeutic regimen.
11
 
A study conducted by Ho and his colleagues in 2008 compare 
three weekly cisplatin vs weekly regimen in locally advanced head 
and neck cancer. They found that the three weekly regimen was 
associated with more treatment delays and the patients received a 
lesser cumulative dose as compared with those getting the weekly 
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regimen. Majority of the patients getting the weekly regimen were 
able to achieve a high cumulative dose of 240mg/m
2
 or more as 
compared with those in the three weekly regimen. 
In a study conducted at the University of Wisconsin  Tray 
Nor et al patients with locally advanced head and neck cancer were 
treated with a weekly cisplatin dose of  30mg/m
2
 along with 
conventionally fractionated radiation of 70 Gy delivered by IMRT. 
The locoregional control and the median overall survival was 
85.5% and 86.9% respectively. The conclusion was that weely 
cisplatin is well tolerated and is efficacious.
12
 
Finally it can be said that the compliance is a significant 
problem with the standard three weekly cisplatin. Almost a third of 
the patients do not receive all the scheduled cycles and subset 
analyses shows that two doses is as efficacious as three doses of 
three weekly cisplatin. Some trials conducted like the RTOG 0129 
suggest that there may be a minimal threshold in the cumulative 
dose  of approximately 200mg/m
2
 that is required to obtain a 
maximal benefit when used concurrently with radiation. Schedules 
that administer chemotherapy more frequently throughout the 
course of RT deliver approximately the same cumulative dose as 
would be achieved through two bolus doses of cisplatin without the 
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excessive toxicity seen with the administration of such a high dose 
of cisplatin as a bolus. 
TRIALS USING GEFITINIB    
In a phase I trial conducted by Changhu Chen et al, where 
Gefitinib with two doses of 250mg and 500mg was combined 
weekly cispatin of 30mg/m
2
 and RT with concomitant boost they 
concluded that the use of daily gefitinib with  concomitant boost 
RT or concurrent  chemoradiotherapy was well tolerated. Also 
the protracted administration of gefitinib upto 2 years at 250mg 
daily was well tolerated. 
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Cohen et al performed a study two cycles of carboplatin with 
paclitaxel induction chemotherapy followed by a split course CCRT 
with %Fu, hydroxyurea and twice daily hyperfractionated RT along 
with daily gefitinib after which Gefitinib was continued for two 
years. CR rate after CCRT was 90%. After median follow-up of 
3.5years, 4-year overall, progression-free, and disease-specific 
survival rates were 74%, 72%, and89%, respectively. High gene 
copy of EGFR was associated with worse overall survival. The 
authors conclude that Gefitinib can be administered with 
hyperfractionated RT followed by maintenance therapy for at least 
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2 years, with outcomes that compare favourably with prior 
experience.
14
 
Hainsworth et al evaluate the feasibility, toxicity and the 
efficacy of the drug Gefitinib added to first line combined modality 
therapy of locally advanced hea and neck squamus cell carcinoma. 
Only patients whose expecte cure rates were low were included in 
the study. Patients received a six week induction course of 
Docetaxel, 5 FU and Gefitinib 250mg. After that patients received 
concurrent chemoradiotherapy with weekly docetaxel and daily 
gefitinib. After the completion of RT Gefitinib was continued till 
disease progression or till a maximum of two years was achieved. 
The estimated 3-year progression-free was 41% and overall 
survival rate was 54%.  The authors concluded that the addition of 
gefitinib had a moderate increase in the toxicity especially in the 
induction phase and although the regimen was efficacious the 
survival rates were similar. The role of EGFR inhibitors in first line 
combined modality therapy in patients with advanced head and 
neck cancer remains undefined. 
15
 
Bella Pajares et al performed a study where they compared 
conventional chemoradiation with cisplatin vs RT with Gefitinib in 
patients who were positive for HPV viral infection. They found 
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after a median follow up of 35 months those who were p16 positive 
showed an improved outcome with RT and Gefitinib compared with 
those treated with RT and cisplatin.(2-year OS 88% vs. 60%, HR 
0.18; 95% CI 0.04 to 0.88; p = 0.01; and 2-year DFS 75% vs. 47%, 
HR 0.17; 95% CI 0.03 to 0.8; p = 0.01). There were no significant 
differences observed in those who were p16 negative (2-year OS 
56% vs. 53%, HR 0.97; 95%CI 0.55 to 1.7; p = 0.9; and 2- year 
DFS 43% vs. 45%, HR 0.99; 95% CI 0.57 to 1.7; p = 0.9). they 
conclude that p16 positive tumors may benefit more from RT plus 
EGFR inhibitor than conventional chemoRT.
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Bhattacharya et al performed a prospective randomised 
control study in Indian patients where they compared 
chemoradiation using weekly cisplatin 30mg/m
2
 and conventional 
fractionated RT to a dose of 66 Gy with or without the addition 
Gefitinib.  They concluded that addition of Gefitinib to standard 
concurrent cisplatin based chemoradiation was well-tolerated, and 
had better overall response and DFS (at 1 year) with addition of 
Gefitinib as compared to standard concurrent chemoradiation.
17
 
Choudhury et al also performed another study where the 
standard concurrent chemoradiation with 60-66GY RT and three 
weekly cisplatin was compared with the regimen along with Daily 
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Gefitinib. At a median follow up of 26 months the response rates 
was statistically more in the Gefitinib arm (91.6% vs 69.5%) and 
had the patients had a longer Disease free survival. The authors 
concluded that the addition of gefitinib to the conventional 
chemoradiation improved the overall response rates and the DFS, 
with an increase in toxicity which was manageable.
18
  
In another trial by Charu Singh, patients of locally advanced 
head and neck cancer were divided into two groups, one group 
received concurrent chemoradiation with 70 Gy RT and weekly 
cisplatin 30mg/m
2
 and the other group received additional Gefitinib 
250mg daily. The overall response rates were 88% Vs 79% in 
favour of the Gefiutinib arm. 79% of the patients achieved a 
complete response in the Gefitinib arm as compared to 62 % in the 
other arm. Except for dermatitis there was no significant difference 
in the toxicity profile of the two arms. The author concluded that 
targeted therapy with Gefitinib and chemoradiation is well tolerated 
with some enhanced but manageable toxicity and has shown to 
improve the local control.
19
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AIMS & OBJECTIVES 
The aim of this study was to evaluate the use of Gefitinib and 
weekly Cisplatin concurrently with conventional radiation in 
locally advanced squamous cell carcinoma of head and neck.  
PRIMARY OBJECTIVE: 
To assess the immediate locoregional response in patients 
with locally advanced head and neck cancer treated with concurrent 
chemoradiation using weekly cisplatin and Tablet Gefitinib.  
SECONDARY OBJECTIVE: 
To assess the acute toxicity of the treatment regimen.  
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MATERIALS AND METHODS 
STUDY DESIGN 
Single arm prospective study with a Phase II design. 
STUDY DURATION 
 March, 2015– August, 2015 
STUDY CENTRE 
Department of Radiotherapy,Barnard Institute of Radiology & 
Oncology, Madras Medical college, Chennai. 
SAMPLE SIZE: 
30 patients presenting to the department of Radiotherapy with 
locally advanced head and neck squamous cell carcinoma fulfilling 
the inclusion criteria were recruited for the study.  
ETHICAL COMMITTEE APPROVAL 
Approval from the institute ethical committee was obtained 
on 11.03.2014. 
INFORMED PATIENT CONSENT: 
All the patients recruited for the study were explained in 
detail about the study, the type of treatment and the advantages and 
disadvantages of the treatment. Once the patient had understood 
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and their queries answered informed consent was obtained from the 
patient, agreeing for their participation in the study. For better 
understanding the informed consent was in the regional language-
Tamil. 
INCLUSION CRITERIA 
 Biopsy proven newly diagnosed squamous cell carcinoma of 
the head and neck 
 Primary tumor sites: oral cavity, oropharynx, hypopharynx, 
larynx 
 Stage III or IVA disease without any evidence of distant 
metastases 
 Age < 70 years 
 ECOG performance Status ≤2 
 No previous surgery or radiotherapy or chemotherapy 
 Adequate bone marrow reserve and normal  hepatic and renal 
functions 
 No associated comorbidities  
 46 
 Signed informed consent prior to initiation of protocol 
specific procedures 
EXCLUSION CRITERIA 
 Non squamous histology 
 Tumours of the nasal cavity, paranasal sinuses, nasopharynx, 
salivary glands 
 Previously received treatment for any other malignancy 
 Inadequate hepatic and renal functions and bone marrow 
reserve 
 Patients not consenting for chemotherapy at any point in the 
treatment  
PRE TREATMENT WORK UP 
 Thorough history and clinical examination 
 Upper aerodigestive tract evaluation by direct and indirect 
laryngoscopy, anterior and posterior rhinoscopy and 
endoscopy if indicated to know the extent of disease and rule 
out a second primary. 
 Biopsy from the primary tumor or fine needle aspiration 
cytology from the metastatic lymph node. 
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 Blood grouping and typing. 
 Complete blood count, Renal function test, Liver function 
test. 
 CT scan of the head and neck, plain and contrast, before 
initiating treatment and also after treatment for response 
assessment. 
 Chest X ray  
 Cardiac evaluation and fitness.  
 Naso-gastric tube insertion if indicated  
 Dental prophylaxis including scaling, dental filling and 
extraction if required.  
 Tumour stage, performance status and weight were recorded, 
and body surface area were recorded 
 Staging was done based on American Joint Committee 
staging manual 7
th
 edition  
 Weekly CBC, RFT, LFT before each cycle of chemotherapy. 
GENERAL PREPARATION OF THE PATIENT 
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Once the patients were enrolled in the study they were 
explained about the procedures involved. For the patients that had 
history of smoking or use of other forms of tobacco, and history of 
alcoholism, they were expressly counseled about the need for 
quitting such habits if they had not already done so. They were 
explained that the use of tobacco and alcohol could hamper the 
treatment outcome. They were also counseled that the continued 
use of these things put them at a higher risk for recurrence of the 
tumor and also the risk of having a new cancer at other parts of the 
body. 
Most of the patients had poor oral hygiene and they were 
advised dental evaluation. As per the requirements dental scaling, 
filling and extraction of teeth were done. A minimum gap of 14 
days was kept between the last dental extraction and the start of 
radiation and chemotherapy to allow sufficient time for healing to 
take place.  
Patients were also explained about the side effects of 
chemoradiation in the head and neck specially mucositis. The 
importance of keeping a good oral hygiene was stressed upon. 
Patients were advised to gargle their mouth atleast 5-6 times per 
day. If commercially available mouth wash were affordable, the 
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patients used them. Otherwise they were taught on how to make 
their mouth wash by dissolving soda bicarbonate and some salt in 
water and use it regularly. Patients were advised to avoid 
toothbrushes having hard bristle for brushing their teeth as it causes 
more injury to the mucosa. Also they were advised to avoid coarse 
rough foods and very hot foods which can cause more injury to the 
mucosa. 
A large percentage of the patients present with dysphagia 
upfront. They were advised for nasogastric tube insertion. For those 
without dysphagia, they were counseled about the possibility of 
developing dysphagia themselves due to mucositis and the need of 
doing a nasogastric insertion at such times. The patients were 
counseled on the importance of taking a good amount of nutrition 
as the exposure to radiation as well as chemotherapy means they 
need extra the anount of what they usually have. they were 
encouraged to take nutrinionally rich local foods including dairy 
products and fruits, eggs etc. 
They were also advised to take at least 1.5-2 litres of water 
per day in regular intervals. All the patients were given protein 
supplements which were available in the department. Also if there 
was a need patients were given parenteral nutrition the form of 
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intravenous fluids and albumin infusions for short courses. The 
weights of patients were monitored regularly to see for any drastic 
change in the weight. 
Patients were also counseled on the importance of the need of 
physical activity during the course of the treatment. Not strenuous 
physical activity, but moderate activity like a walk around the 
campus. Studies has shown that some form of physical activity 
during the course of treatment reduces the incidences of fatigue and 
also improves the quality of life and the psychological state of the 
patient. 
Patients and their attenders were counseled about the 
importance of sticking to the treatment schedule and to avoid any 
treatment breaks unless otherwise indicated due to the development 
of side effects. 
For those patients that had their homes nearby the hospital, 
they were encouraged to get their radiation daily from their homes 
as out-patients. They were admitted on their chemo days and then 
discharged after chemotherapy. They were monitored everyday 
when they came for radiation for signs and symptoms of radiation 
and chemotherapy. 
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TREATMENT PROTOCOL 
30 patients of locally advanced squamous cell carcinoma of 
the  head and neck enrolled in the study underwent the full pre-
treatment work up and preparation. They were then started on 
concurrent chemoradiation using weekly cisplatin and daily tablet 
Gefitinib.  
RADIATION THERAPY: 
Patients were treated using theratron phoenix telecobalt 
machine with conventional 2D planning. They were treated using 
bilateral opposed fields which included the primary and the nodes. 
The patients were treated with conventional 2 Gy per fraction 5 
fractions per week to a total dose of 66 Gy. At 40 Gy the posterior 
border was shifted anteriorly so as to avoid the spinal cord. The 
planned duration of the treatment was six and half weeks.    
CHEMOTHERAPY 
Patients were started on chemotherapy from day 1 of 
radiation. Injection Cisplatin 30mg/m
2
 diluted in 500ml of Normal 
Saline was infused over 2 hours after premedications. Radiation 
was started within one hour of completion of chemotherapy. 
Patients received the subsequent cycles of chemotherapy at one 
week intervals.  
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Patients also received tablet Gefitinib 250mg once daily 
before Radiation. Patients were advised to take the tablets about 4 
hours before the start of RT. The peak plasma level of Gefitinib is 
reached by 3-7 hours of oral intake.   
PREMEDICATION 
Patients were hydrated with 1L of NS before the start of 
chemotherapy along with following premedications. 
Inj. Ondansetron 8 mg IV. 
Inj. Dexamethasone 8mg IV. 
Inj. Ranitidine 50 mg IV. 
Inj. Chlorpheniramine 4mg IV. 
Injection Cisplatin 30mg/m
2
 mixed in 1 pint of NS was 
infused over 2 hours after which patients received pint  of NS.  
ASSESSMENT DURING CHEMORADIATION: 
Toxicity Assessment: 
The patients were examined everyday to see for any toxicities 
like mucositis, skin reactions, dysphagia, laryngitis, xerostomia. 
The findings were recorded and graded according to the RTOG 
acute toxicity criteria. Other effects of chemotherapy like nausea, 
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vomiting, diarrhea, skin rash were also looked for and graded. 
Blood tests were done every week before the initiation of 
chemotherapy and then if there was any abnormality like anemia or 
leucopenia, they  were corrected by blood transfusions and G-CSF 
injections. For any abnormalities in the renal and liver functions, 
opinions from the specialist like nephrologist were obtained.  
RESPONSE EVALUATION: 
Clinical evaluation and imging by using contrast enhanced 
CT were done at sfter 6 weeks of completion of ChemoRT for 
response assessment.   
Response to treatment was described based on the Response 
Evaluation Criteria in Solid Tumors (RECIST 1.1 version) Criteria.  
 COMPLETE RESPONSE: Disappearance of all target 
lesions; malignant nodes <10 mm.  
 PARTIAL RESPONSE: At least 30% reduction in the sum 
of the longest diameter of target lesions, taking as reference 
the baseline study  
 STABLE DISEASE: Neither partial response nor progressive 
disease criteria are met, in a minimum time set by the 
protocol.  
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 PROGRESSIVE DISEASE: At least 20% increase in the 
sum of the diameter, with a minimum absolute increase of 5 
mm, taking as reference the smallest sum in the study or 
appearance of new lesions.  
FOLLOW UP 
 The patients were advised to come after 6 weeks for response 
assessment after the completion of chemoradiation or to 
review SOS if they developed any significant problems in 
between.  
 After the intial response assessment patients were kept on 
monthly follow up as per our institution protocol.  
 They were advised continued abstinence from the use of 
tobacco and alcohol, to keep good oral hygiene.  
 Other complaints and symptoms were dealt with as necessary.  
 STATISTICAL ANALYSIS: 
All the results were compiled and analysed and expressed in 
terms of percentage. This is a single arm study with a sample size 
of 30, hence the statistical significance of the study cannot be 
commented upon. 
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RESULT AND ANALYSIS 
All of the 30 patients that were included in the study 
completed the full course of treatment and were available for 
analysis. The following results were compiled.  
PATIENT CHARACTERISTICS 
GENDER 
As expected, males were more as compared to the females. 
This reflects the more prevalence of risk factors of the use of 
tobacco and alcohol in the male population as compared to the 
female counterpart. Fig 2 
Table no: 1, GENDER DISTRIBUTION OF THE STUDY 
POPULATION 
Sex No. Of patients Percentage 
Male 25 83.3% 
Female 5 16.7% 
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AGE DISTRIBUTION: 
Almost half of the patients were in the 51-60 years age group 
(46.66%). The percentage of patients in the younger age group is 
also high. The oldest patient included in the study was 68 years old. 
The youngest was 32years. Both were males associated with the use 
of tobacco. Fig 3  
Table No-2: Age Distribution Of The Study Population 
PERSONAL HABITS 
Majority of the patients had history (86.66%) of use of 
tobacco in its various forms. 14 of them had concomitant use of 
alcohol (46.66%). Only 4 of them did not give any history of use of 
tobacco or alcohol, all of whom were females. Fig 4 
Table no: 3 
Habits No.of patients Percentage 
Tobacco (Smoking) 21 70% 
Tobacco (Smokeless) 12 40% 
Alcohol 14 46.66% 
None 4 13% 
Age Group Number Percentage 
31- 40yrs 4 13.33% 
41 -50yrs 8 26.66% 
51-60yrs 14 46.66% 
61-70yrs 4 13.33% 
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SYMPTOMS AND SIGNS 
Majority of the patients presented with the complaint of pain 
and a equal number with the complaint of dysphagia. 15 (53.33%) 
patients presented with the complaint of neck swelling. 
Table no: 4, symptoms/signs 
Presenting symptoms/signs Number Percentage 
Pain 18 60% 
Ulcer/ Growth 6 20% 
Dysphagia 17 56.66% 
Odynophagia 9 30% 
Neck swelling 16 53.33% 
Voice change 5 16.66% 
DURATION OF SYMPTOMS ACCORDING TO SITE WISE 
Mean duration of the presenting symptoms were similar 
amongst the different subsites. Longest duration of symptom was a 
laryngeal cancer where patient presented with a history of 
hoarseness of voice for 6 months associated with progressive 
dysphagia for the past 2 months 
Table 5.    
Site Mean Duration(in months) 
Oral cavity 3 
Oropharynx 3.3 
Larynx 3.6 
Hypopharynx 3.1 
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  PERFORMANCE STATUS  
Most of the patients had a ECOG performance status of 2 at 
the time of presentation. Fig 6 
Table No:6, ECOG performance status 
ECOG No.of patients Percentage 
ECOG 0 8 26.7% 
ECOG 1 17 56.6% 
ECOG 2 5 16.6% 
PRIMARY SITE 
Oropharynx and hypopharynx were the most common sites 
for primary. Each making up 30% of the study population. Fig 7   
Table no:7 
Primary site Number Percentage 
Oral cavity 6 20% 
Oropharynx 9 30% 
Hypopharynx 9 30% 
Larynx 6 20% 
Comparing the various subsites, the most common were in the 
post cricoids region, followed by the supraglottis, the posterior 1/3 
tongue and the tonsil.  
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Table No: 8, subsite analysis 
Subsite Number Percentage 
Tongue 4 20% 
Floor of mouth 1 3.33% 
Buccal mucosa 1 3.33% 
Posterior 1/3 tongue 5 16.66% 
Tonsil 4 13.33% 
Post cricoid 2 6.66% 
Pyriform sinus 7 23.33% 
Supraglottis 6 20% 
TUMOR STAGE 
Most of the patients had a T4 (56.66%) disease at the time if 
presentation. Fig 8 
Table no:9, Tumor stage  
T stage Number Percentage 
T2 1 3.33% 
T3 12 40% 
T4 17 56.66% 
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NODAL STAGE 
 N2 was the most common nodal presentation (70%). 10% of 
the patients did not have any clinically significant nodes at the time 
of presentation. Fig 9 
 Table no: 10, Nodal stage 
Nodal stage Number Percentage 
N0 3 10% 
N1 6 20% 
N2 21 70% 
STAGE GROUPING OF THE STUDY SAMPLE 
Stage IVA was the most common stage at the time of 
presentation (80%) fig 10 
Table no: 11, stage grouping 
Stage grouping Number Percentage 
STAGE III 6 20% 
STAGE IV A 24 80% 
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HISTOLOGICAL DIFFERENTIATION 
Majority of the tumors were moderately differentiated (60%) Fig 11 
Table No:12, Histological differentiation 
Histological differentiation Number Percentage 
Well differentiation 4 13.33% 
Moderately differentiated 18 60% 
Poorly differentiated 8 26.66% 
TREATMENT RESULTS 
All 30 patients that were initially enrolled in the study were 
able to fully complete the treatment protocol. They were assessed 
clinically and by CT with contrast after 6 weeks of treatment for 
response evaluation and thendescribed as per the RECIST criteria.  
 RESPONSE RESULTS 
Overall response rate was 100% of which 76.6% of the 
patients had complete response and 23.3% had partial response. 
There was no static response or progressive disease in the 
study.(figure no:12) 
Table no:13, Response results 
Response Number Percentage 
Complete response 23 76.66% 
Partial presponse 7 23.33% 
 62 
SITE VS RESPONSE 
Oropharynx, hypopharynx and laryngeal cancers had good 
response rates as compared to oral cavity cancers. Fig 13 
Table no:14, Site Vs Response 
Site 
Complete 
Response 
Partial response 
Oralcavity 4(66.6%) 2(33.3%) 
Oropharynx 7(77.8%) 2(22.2%) 
Hypopharynx 7(77.8%) 2(22.2%) 
Larynx 5(83.3%) 1(16.66%) 
TUMOR STAGE VS RESPONSE 
T3 diseases had a 83.3% complete response rate as compared 
to T4 lesions which had 70.6% complete response rates. Fig 14 
Table no: 15, Tumor Stage Vs Response 
Tumor stage 
Complete 
Response 
Partial response 
T2 1(100%) 0 
T3 10(83.3%) 2(16.66%) 
T4 12(70.6%) 5(29.4%) 
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NODAL STAGE VS RESPONSE 
All N1 and N2A diseases had 100% complete response. The 
complete response rates for N2B and N2C diseases were 85.75% 
and 60% respectively Fig 15  
Table no:16, Nodal Stage Vs Response  
Nodal stage Complete Response Partial response 
NO 3(100%) 0 
N1 6(100%) 0 
N2a 4(100%) 0 
N2b 6(85.7) 1(14.3%) 
N2c 6(60%) 4(40%) 
HISTOLOGICAL DIFFERENTIATION VS RESPONSE 
The response rates correlated with the histological 
differentiation with poorly and moderately differentiated tumors 
having higher rates of complete response as compared to the well 
differentiated primaries. Fig 16  
Table no: 17, Histological differentiation Vs response.  
Histologic differentiation Complete response Partial response 
Well differentiated 2(50%) 2(50%) 
Moderately differentiated 14(77.8%) 4(22.2%) 
Poorly differentiated 7(87.5%) 1(12.5%) 
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PERFORMANCE STATUS VS RESPONSE 
The response rates were similar between patients having 
ECOG performance status of 0 or 1 OR 2. Fig 17 
Table no: 18, ECOG Vs Response 
ECOG Complete response Partial response 
0 6(75%) 2(25%) 
1 13(76.5%) 4(23.5%) 
2 4(80%) 1(20%) 
PRIMARY AND NODAL SITES – DIFFERENTIAL 
RESPONSE 
In this study the complete response rate in the primary site 
was 76.6% whereas in that of the nodal region was 83.3%. 
AGE VS RESPONSE 
The response rates across the age groups were similar in this 
study Fig18 
Table no: 19, Age Vs Response 
Age group Complete response Partial response 
31-40Yrs 3(75%) 1(25%) 
41-50Yrs 6(75%) 2(25%) 
51-60Yrs 14(78.5%) 3(21.4%) 
61-70Yrs 3(75%) 1(25%) 
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STAGE VS RESPONSE 
Stage III patients had better complete response rates (86.66%) 
as compared with stage IVA disease (75%)  fig 19 
Table no :20, Stage Vs Response 
Stage Complete response Partial response 
STAGE III 5(83.33%) 1(16.66%) 
STAGE IV  18(75%) 6(25%) 
TREATMENT BREAK VS RESPONSE 
Prolongation of the total treatment time adversely effects the 
treatment outcome and survival. So it is important that that the 
treatment gets completed without any break.  
In this study group 56.6% (17) of the patients had completed 
the treatment without any break.  The main cause of treatment 
break was mucositis. In this study those who had a longer duration 
of break in the treatment had more treatment failure rates as 
compared with those who completed the treatment with no breaks 
or had minimal breaks of 1-5 days.   Fig 20 
Table no: 21, Treatment break Vs Response 
Treatment break Number Complete response Partial response 
No break 17 14(82.3%) 3(17.6%) 
1-5 Days 8 6(75%) 2(25%) 
> 6 Days 5 3(60%) 2(40%) 
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TREATMENT RELATED ACUTE TOXICITIES 
MUCOSITIS 
In this study all patients developed some form of mucositis.  
As expected there was high incidence of mucositis in this study. 
Overall 70% had grade 1or 2 mucositis and 30% had grade 3 or 4 
mucositis requiring treatment breaks. Around 43% had grade 2 
mucositis and 26% had grade 3 mucositis. Only one patient had 
grade 4 mucositis.  
SKIN REACTION 
All patients had some form of skin reaction however there 
was no grade 3 or 4 reactions in this study. 80% had grade 1 
reaction and the remaining had grade 2. 
SALIVARY GLAND /XEROSTOMIA 
The salivary glands has a comparatively low tolerance dose 
and is reflected in the results of this study. 73.3% of the patients 
had grade 1 reraction and the remaining had grade 2. There were no 
grade 4 reactions in this study. 
PHARYNGITIS AND DYSPHAGIA 
During the course of the treatment all patients had some form 
of dysphagia. 33% had grade 1 dysphagia, around 36% had grade 2 
and 30% had grade 3 dysphagia.  
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LARYNGITIS 
Around 33% had grade 1 laryngitis, 46% had grade 2 and the 
remaining had grade 3 laryngitis. 
Table no:22, Acute toxicity Fig 21 
SYSTEMIC TOXICITY 
NAUSEA 
73.3% of the patients had grade 1 nausea. Only 1 person had 
grade 3 nausea. 
 
Acute 
Toxicity 
Grade 
0 
Grade 
1 
Grade 
2 
Grade 
3 
Grade 
4 
Skin reactions 0 23 
(76.66%) 
5 
(16.66%) 
2 
(6.66%) 
0 
 
Mucositis 
 
0 
8 
(26.6%) 
13 
(43.3%) 
8 
(26.6%) 
1 
(3%) 
Salivary gland 0 22 
(73.3%) 
8 
(26.7%) 
__ 0 
Pharyngitis/ 
Dysphagia 
0 10 
(33.33%) 
11 
(36.67%) 
9 
(30%) 
0 
 
Laryngitis 
0 10 
(33.33%) 
14 
(46.67%) 
6 
(20%) 
0 
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VOMITING  
76.6% of patients had vomiting commonly after the infusion 
of chemotherapy all of which responded to the routine anti-emetic 
measures. The remaining had grade 2 nausea. There was no episode 
of severe vomiting in any of the patients. 
DIARRHOEA 
4 patients had grade 1 diarrhea and only 1 patient had grade 2 
diarrhoea. There were no grade 3 or 4 toxicities  
GEFITINIB RELATED SKIN RASH 
Only one patient developed the classical skin rash associated 
with the use of gefitinib. It was a grade 1 skin reaction and did not 
necessitate the need for suspending the drug. It developed during 
the 3
rd
 week of treatment and resolved with symptomatic treatment.  
Table no: 23,Systemic toxicity Fig 22 
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 
Nausea 22 (73.3%) 7 (23.3%) 1 (3.33%) 0 
Vomitting 23 (76.6%) 7 (23.3%) 0 0 
Diahorrea 4 (13.3%) 1 (3.33%) 0 0 
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HEMATOLOGICAL TOXICITY 
ANAEMIA 
The hemoglobin of all the patients were >11gm% before the start 
of treatment. 5 patients had hemoglobin below 11gm% and were 
corrected by transfusion before the start of treatment. During the course 
of treatment, 9 patients developed grade 1 anemia and 2 of them 
developed grade 2 anemia, which was corrected with blood transfusion. 
Table no: 24, Anemia Fig 23 
Anemia Number Percentage 
GRADE 0 19 63.3% 
GRADE 1 9 30% 
GRADE 2 2 6.7% 
GRADE 3 0 0 
GRADE 4 0 0 
LEUCOPENIA  
Of the 30 patients, only two developed leucopenia grade 1. 
All the rest had total count> 4000/mm
2
 throughtout the course of 
treatment. There were no episodes of febrile neutropenia or 
thrombocytopenia.  
RENAL TOXICITY 
The renal parameters of all the patients were normal 
throughout the course of treatment.  
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DISCUSSION 
Squamous cell carcinoma of the head and neck is one of the 
most prevalent cancers in India and has a high social and economic 
impact. Majority of the patients present in the locally advanced 
stage where surgical resection is either not possible or is associated 
with a lot of morbidity. Historically such patients were treated with 
local RT alone where the local control rates were between 50-70% 
and the 5 year survival was a dismal 10-20%
20
.  
There was a definite rationale for the combined use of 
chemotherapy and radiation in locally advanced head and neck 
cancer. Chemotherapy sensitizes  tumors  to radiotherapy  by  
inhibiting  tumor  repopulation,  it preferentially  kills the  hypoxic  
cells,  inhibiting  the  repair  of sublethal damage caused by 
radiation, it sterilizes the micrometastatic disease outside the 
radiation fields and also decreases the tumor mass which  leads to 
improved blood supply and reoxygenation thus potentiating the 
effect of radiation. Fractionated radiotherapy,  sensitizes  tumors  to  
chemotherapy  by  inhibiting  the  repair  caused by chemotherapy. 
It also decreases the size of the tumor causing improved blood 
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supply to the tumor such that the chemo can more easily reach the 
tumor cells leading to more cytotoxic effect. 
 Several trials investigating the feasibility as well the 
improvement of outcomes by using chemotherapy along with 
radiation were performed. In most of the trials cisplatin was the 
mainstay of chemotherapy and it was used alone or in combination 
with some other agents. The expected theoretical advantage of 
adding another cytotoxic agent in the form of chemotherapy to that 
of radiation was clearly demonstrated in these trials and was 
confirmed by a number of meta-analysis.  
Many meta-analyses have been conducted to show whether 
chemo-radiotherapy association is better than radiotherapy alone as 
concerns LRC or survival
21-23
. Among these meta-analyses the most 
well known and important one is the Meta- Analysis on 
Chemotherapy on Head and Neck cancer (MACH-NC) published by 
Pignon et al
8
. It showed that adding chemotherapy to radiation had 
the following advantages in locally advanced cancer of the head 
and neck: 
1) The use of chemotherapy increased the overall survival at 5 
years by 5% irrespective of the timing of association 
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2) The concurrent use of chemotherapy with radiation improved 
the overall survival by 8% 
3) The use of neoadjuvant chemotherapy followed  by radiation 
alone is less effective as compared to concurrent 
chemoradiation 
4) The use of cisplatin as the chemotherapy has evident benefit  
5) The use of combination chemotherapy does not seem to 
provide added advantage over the use of single agent.  
6) And as the age of the patient increase over 70, the benefit of 
adding chemotherapy is less evident. 
As of now the standard of care for all those locally advanced 
unresectable head and neck cancer is concurrent chemoradiation 
with a radiation dose of upto 70 Gy and three weekly cisplatin of 
80-100mg/m
2
. However the three weekly regimen is associated with 
a number of toxicities and poor compliance. Literature wise 
evidence exists that the weekly regimen of cisplatin is as 
efficacious as the three weekly regimen as long as a minimum 
threshold cumulative dose of 200mg/m
2
 is achieved. This comes 
with a significant lesser toxicity in the weekly arm. In a study 
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conducted in our department, the weekly regimen was as 
efficacious as the three weekly regimen with lower toxicities.  
CISPLATIN 
WITH 
RADIATION 
COMPLETE 
RESPONSE 
RATE IN % 
PARTIAL 
RESPONSE 
RATE IN % 
THREE 
WEEKLY 
64 36 
WEEKLY 62 38 
The use of concurrent chemoradiation in locally advanced 
setting is now the standard of treatment worldwide. With this 
treatment the overall survival has increased to about 50-60% with 
the best of treatment. However even with the use of a variety of 
treatment approaches the overall survival has failed to improve 
significantly. Several trials are going on for the development of 
new drugs and that may help improve the overall survival.  
One of these fields is that of molecular biology. It is said that 
to defeat an enemy one must know the enemy. Better the knowledge 
easier will it be to fight. The same principle can be applied to the 
field of oncology also. From the knowledge that all cancers are not 
the same but of different histology and morphology, and has a 
different behavior to knowing that there are variations within the 
same histology our knowledge has now expanded to include the 
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domain of molecular biology. A better understanding of the 
pathogenesis of cancer the various mechanisms, growth factors and 
pathways that are involved and knowledge of proteins involved in 
these activities has allowed for their targeting by use of various 
drugs. They offer a very attractive prospect where the tumor cells 
can be targeted specifically instead of the mass general cytotoxicity 
offered by the other chemotherapies. Thus, decreasing the toxicity 
of treatment and also improving the outcome.   
The EGFR pathway provides a promising pathway for 
targeting as almost 90% of the head and neck squamous cell 
carcinoma over express this receptor. It plays a pivotal role in 
tumor growth, invasion, angiogenesis and metastasis. Preclinical 
trials have shown that the addition of a anti-EGFR has a synergistic 
effect with radiation. Cetuximab (Erbitux) is a monoclonal antibody 
specific against the EGFR receptor. In a landmark trial by Bonner 
et al it was clearly demonstrated that the concomitant use of RT 
plus Cetuximab significantly improved the Locoregional Control 
Rate, the Disease free Survival and overall survival in patients with 
locally advanced head and neck squamous cell carcinoma
D1
.  Since 
then a number of trials have been done researching the benefit of 
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adding targeted therapy along the standard chemoradiation 
protocol.  
The other group of drugs against EGFR are the TKIs like 
Gefitinib and Erlotinib. These drugs are even less toxic than the 
monoclonal antibodies. They have proven their worth in lung 
cancer where recent trials have shown that the use of TKIs 
significantly improves the progression free survival and the overall 
survival in specific subset of patients having the EGFR mutation.  
A number of trials have been done in head and neck 
squamous cell carcinoma using these TKIs with the believe that 
their use will have a significant impact on the treatment outcome 
considering the high expression of EGFR in these patients. These 
trials have been done in the recurrent and metastatic setting as well 
as in those with newly diagnosed disease. However the results have 
been mixed and the benefit not as clear cut as that seen in lung 
cancer. Potential mechanisms for lack of response to EGFR 
inhibition in HNSCC include constitutive activation of signaling 
pathways independent of EGFR, as well as genetic aberrations 
causing dysregulation of the cell cycle. EGFR-directed therapy may 
be optimized by identifying and selecting those HNSCC patients 
most likely to benefit  from  EGFR  inhibition.  Resistance  to  
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EGFR  inhibition  may  be  circumvented  by combination therapy  
employing  EGFR  inhibitors together  with  other  treatment  
modalities  (Kalyankrishna & Grandis 2006)
24
.    
In several phase II trials, the use of gefitinib in combination 
with the standard chemoradiotherapy has shown to improve the 
immediate response rates and the locoregional control  rates. But the 
impact of the addition of Gefitinib on the overall survival is yet to 
be assessed in a large scale randomized trial. Several trials are 
ongoing which will hopefully provide a definite answer for this 
question in the near future.   
Keeping the various studies and findings in mind, we wanted 
to evaluate whether the addition of Gefitinib could improve he 
treatment outcome in our patients with locally advanced head and 
neck cancer. 
In this present study the overall response rate (CR+PR) was 
100% with 76% of the patients achieving a compete response and 
the remaining had partial response. There was no significant 
association of the response to therapy when compared with the 
gender of the patient, the age of diagnosis, performance status of 
the patient.  
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 In this study, primary tumors in the oropahrynx, 
hypopharynx and the larynx had a better response to treatment as 
compared to those in the oral cavity. This may be due to the fact 
that most of the oral cavity tumors were well differentiated and had 
a poor response to treatment. This also corroborated with the 
finding where poorly differentiated tumors had better treatment 
response rates as compared with the well differentiated histologies.  
 Tumors with lesser volume of disease i.e. T3 diseases 
had better response rates as compared with the T4 diseases and the 
same findings were seen in the nodal disease where N1 and N2A 
tumors responded better than the N2B and 2C tumors. Also the 
response rates in the nodal region was better than that in the 
primary with 83% achieving a complete response in the nodal site 
as vompared to 76% in the primary. 
Also those who had a break in the continuity of the treatment 
had a worse outcome as compared with those who had no breaks. 
Those who had no treatment break had complete response rates of 
82%, those with less than5 days break ahd a CR of 75% and those 
who had more than 5 days of break had a CR of 60 %. This reflects 
the importance of completing the treatment without any break as 
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the problem of accelerated repopulation can lead to treatment 
failure. 
Compared with the historical data and also the department 
data, the use of gefitinib along with chemoradiation resulted in 
better response rates with 76% of the patients achieving a complete 
response as compared to 64-65% in the historical and department 
data. But this finding is not statistically significant due to the small 
study population. 
Even though all of the patients developed some form of acute 
toxicity to chemoradiation, the rates of grade 3 and 4 toxicities 
were low. Only 6% of the patients had grade 3 skin reaction and no 
grade 4 reactins. Also the rates of grade 3 and grade 4 mucositis 
were 26% and 3% respectively. The incidence of grade 3 
pharyngitis and laryngitis were 30% and 20% respectively. There 
were no grade 4 reactions.  
Other systemic toxicities like nausea, vomiting, diarrhea were 
also seen in the patients but all were manageable with routine anti 
emetic measures. Only 1 patient had grade 3 nausea. Non of the 
patients had grade 3 diarrhoea or vomiting. 
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The hematogical toxicity was also minimal with no incidence 
of grade 3 or 4 toxicity. 6% of the patients had grade 2 anemia 
which was corrected with blood transfusion. There was no 
incidence of any febrile neutropenia or thrombocytopenia in the 
patients. There was no incidence of any renal toxicity or liver 
toxicity in any of the patients.  
 Only one patient developed the classical rash that is 
associated with the use of Gefitinib. It was a grade 1 reaction and 
resolved by cponservative management alone. No treatment break 
was required.         
In our study the addition of Gefitinib to concurrent 
chemoradiation was found to be well tolerated. Compared with the 
historical data in our department as well as the world literature the 
response rates to our treatment was better with higher percentage of 
the patients achieving a complete response. But the sample size is 
small and this finding even though encouraging is not statistically 
significant. The regimen also had a good compliance rate with a 
large proportion of the patients completing the treatment without 
any break or a minimal break.  
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The major limitations of this study included its small sample 
size and short follow-up period. It is known that most of the 
SCCHN over-express EGFR which adds to the rational of using 
Gefitinib in this disease. However, EGFR Expression study could 
not be done in all patients due to financial reasons as it involves 
considerable cost. So, a subgroup analysis with EGFR wild type, 
mutated or over-expression parameters was not possible. Larger 
multi-centric trials are needed to confirm and validate the 
encouraging results of our study before Gefitinib could be 
recommended in routine clinical practice along with concurrent 
cisplatin-based chemo-radiation which is the current standard of 
care in locally advanced SCCHN. 
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CONCLUSION 
In conclusion, it can be stated that the problem of head and 
neck cancer continues to grow with the passing years and efforts to 
curb the disease has failed to make a significant impact on this 
problem. Hence more amount of patients are presenting with locally 
advanced cancers. In such patients the addition of Gefitinib to the 
standard concurrent chemoradiation protocol seems to be a good 
option showing a better response rates than the standard arm. The 
regimen is also well tolerated with a severe increase in the toxicity 
and patient compliance is good. But this study was done in a small 
study sample and faile to reach statistical significance. Larger trials 
are needed to validate these encouraging findings and to more 
clearly define the role of Gefitinib in the management of locally 
advanced head and neck cancer. 
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FIG 12 OVERALL RESPONSE RATES 
 
FIG 13 SITE VS RESPONSE 
4
7 7
5
2 2 2
1
0
1
2
3
4
5
6
7
8
oral cavity oropharynx hypopharynx larynx
complete partial
 
 
 24 
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FIG 20 TREATMENT BREAK VS RESPONSE 
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ANNEXURE I 
RTOG - ACUTE RADIATION 
MORBIDITY SCORING CRITERIA 
Grade  0 1 2 3 4 
Skin No 
change 
over 
baselin
e 
Follicular, faint 
or dull 
erythema/ 
epilation/dry 
desquamation/ 
decreased 
sweating 
Tender or 
bright 
erythema, 
patchy moist 
desquamation
/ moderate 
edema 
Confluent, 
moist 
desquamatio
n other than 
skin folds, 
pitting 
edema 
Ulceration, 
hemorrhage
, necrosis 
Mucous 
Membrane 
No 
change 
over 
baselin
e 
Injection/ may 
experience mild 
pain not 
requiring 
analgesic 
Patchy 
mucositis 
which may 
produce an 
inflammatory 
serosanguinit
is discharge/ 
may 
experience 
moderate 
pain 
requiring 
analgesia 
Confluent 
fibrinous 
mucositis/ 
may include 
severe pain 
requiring 
narcotic 
Ulceration, 
hemorrhage 
or necrosis 
Pharynx 
&Esophagu
s 
No 
change 
over 
baselin
e 
Mild dysphagia 
or odynophagia/ 
may require 
topical 
anesthetic or 
non-narcotic 
analgesics/ may 
require soft diet 
Moderate 
dysphagia or 
odynophagia/ 
may require 
narcotic 
analgesics/ 
may require 
puree or 
liquid diet 
Severe 
dysphagia or 
odynophagia 
with 
dehydration 
or weight 
loss(>15% 
from pre-
treatment 
baseline) 
requiring N-
G feeding 
tube, I.V. 
fluids or 
hyper 
alimentation 
Complete 
obstruction, 
ulceration, 
perforation, 
fistula 
SALIVAR
Y GLAND 
No 
change 
over 
baselin
e 
Mild mouth 
dryness/ 
slightly 
thickened 
saliva/ may 
have slightly 
altered taste 
Moderate to 
complete 
dryness/ 
thick, sticky 
saliva/ 
markedly 
altered taste 
 Acute 
salivary 
gland 
necrosis 
Grade  0 1 2 3 4 
such as metallic 
taste/ these 
changes not 
reflected in 
alteration in 
baseline feeding 
behavior, such 
as increased use 
of liquids with 
meals 
 
 
Laryngitis 
No 
change 
over 
baselin
e 
Mild or 
intermittent 
hoarseness/coug
h not requiring 
antitussive/ 
erythema of 
mucosa 
Persistent 
hoarseness 
but able to 
vocalize/ 
referred ear 
pain, sore 
throat, patchy 
fibrinous 
exudate or 
mild 
arytenoid 
edema not 
requiring 
narcotic/  
antitussive 
Whispered 
speech, 
throat pain 
or referred 
ear pain 
requiring 
narcotic/ 
confluent 
fibrinous 
exudate, 
marked 
arytenoid 
edema 
Marked 
dyspnea, 
stridor or 
hemoptysis 
with 
tracheostom
y or 
intubation 
necessary 
 
HEMATOLOGICAL TOXICITY 
Grade  0 1 2 3 4 
HEMATOLOGIC 
WBC (X 1000) 
>=4.0 3.0 - 
<4.0 
2.0 - 
<3.0 
1.0 - 
<2.0 
<1.0 
PLATELETS (X 
1000) 
>=100 75 - 
<100 
50 - 
<75 
25 - 
<50 
<25 or 
spontaneous 
bleeding 
NEUTROPHILS >=1.9 1.5 - 
<1.9 
1.0 - 
<1.5 
0.5 - 
<1.0 
<0.5 or 
sepsis 
0HEMOGLOBIN 
(GM %) 
>11 11-
9.5 
<9.5 
- 7.5 
<7.5 
- 5.0 
- 
 
 
ANNEXURE II 
COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS CTCAE VERSION 
4. 
GRADE 1 2 3 4 5 
Nausea Loss of appetite 
without 
alteration in 
eating habits 
Oral intake 
decreased without 
significant weight 
loss, dehydration 
or malnutrition. 
Inadequate oral 
caloric or fluid 
intake, tube feeding, 
TPN, or 
hospitalization 
indicated. 
- - 
Vomiti
ng 
1-2 episodes  
(separated by 
5 minutes) in 
24 hrs 
3-5 episodes 
(separated by 5 
minutes) in 24 
hrs 
>/=6 episodes 
(separated by 5 
minutes) in 24 
hrs,tubefeeding,
TPN or 
hospitalization 
indicated 
Life-threatening 
consequences,ur
gent intervention 
indicated 
deat
h 
Diarrhe
a 
Increase of 
<4stools per 
day over 
baseline 
Increase of 4-
6 stools per 
day over the 
baseline 
Increase of >= 
7 stools per 
day over the 
baseline, 
incontinence, 
hospitilisation 
required 
Life threatening 
consequences. 
Urgent 
intervention 
required 
Deat
h 
Rash Macules/pap
ules 
involving<10
% of BSA 
with or 
without 
symptoms 
like pain, 
pruritus 
Macules/pap
ules 
involving 10-
3-% of BSA 
with or 
without 
stmptoms  
Macules/papul
es involving 
>30% of BSA 
with or 
without 
symptoms. 
Limiting 
instrumental 
ADL 
Macules/ 
papules 
involving abd % 
if the body 
surface which 
may or may not 
abe associated 
with symptoms 
of ruritus or 
tenderness, 
associated with 
severe 
superinfection 
requiring iv 
antibiotics 
deat
h 
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